1
|
Freppel M, Mention K, Renom G, Lambilliotte A, Barbati M. Informing parents of newborns with sickle cell trait detected at neonatal screening: A northern France experience. Pediatr Blood Cancer 2024; 71:e31174. [PMID: 38978315 DOI: 10.1002/pbc.31174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/10/2024] [Revised: 06/14/2024] [Accepted: 06/17/2024] [Indexed: 07/10/2024]
Abstract
Neonatal screening for sickle cell disease (SCD) in France, targeted since 1995, indirectly detects newborns with sickle cell trait (SCT). Information about carrier status must be communicated to families in accordance with the 2006 National Consultative Ethics Committee recommendations; however, no national protocol for this exists. In the departments of Nord and Pas-de-Calais, the Regional Neonatal Screening Center transmits this information through a general practitioner (GP). This study aimed to assess the success rate of local practices in transmitting SCT information to parents. The secondary objectives included explaining transmission failures, evaluating post-information couple screening rates, and conducting a nationwide evaluation of SCT information dissemination. In this retrospective, multicenter study, family doctors were surveyed regarding newborns screened for SCT between January 1 and December 31, 2020, in the Nord and Pas-de-Calais departments. Among the 260 screened newborns, 197 were eligible for analysis. Results showed that 31.2% of newborns with SCT had their GP definitively sharing information with their parents. Based on this information, subsequent parental screening accounted for 13.6% of cases. The reasons cited by the GP for failing to convey information included elusive families (52.5%), unfamiliarity or refusal of the role (35%), limited SCD knowledge (25%), and ethical considerations (12.5%). This study highlights the difficulty and heterogeneity in transmitting carrier status information to parents of newborns with SCT. Our findings could serve as a foundation for the development of new methods for information transmission, given the generalization of neonatal screening for SCD by the French National Authority for Health.
Collapse
Affiliation(s)
- Malo Freppel
- Lille University Hospital (CHU Lille), Lille, France
| | - Karine Mention
- Regional Neonatal Screening Center (CRDN Hauts-de-France), Lille University Hospital (CHU Lille), Lille, France
| | - Gilles Renom
- Perinatal Screening Laboratory, Center for Biology and Pathology, Lille University Hospital (CHU Lille), Lille, France
| | | | | |
Collapse
|
2
|
Elenga N. Genetic Information to Share with Parents when Newborn Screening Reveals the Presence of Sickle Cell Trait. Int J Pediatr 2024; 2024:8910397. [PMID: 38433874 PMCID: PMC10904677 DOI: 10.1155/2024/8910397] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/29/2023] [Revised: 01/16/2024] [Accepted: 01/29/2024] [Indexed: 03/05/2024] Open
Abstract
The primary purpose of newborn screening for sickle cell disease is to diagnose the disease before the appearance of symptoms and to initiate early treatment. To answer the question "What genetic information needs to be communicated to parents when newborn screening reveals the presence of a sickle cell trait," we conducted a survey using a self-administered online questionnaire. We received responses from 122 healthcare workers and members of sickle cell disease associations, in France and French overseas departments. Our results showed similar positions on this issue. The information conveyed is not consistent and is the result of grassroots initiatives. The negative consequences generated by this information could be reduced when this information is delivered by a multidisciplinary team, within the framework of a dedicated consultation. This information on sickle cell trait status should be given in at least three key periods: the neonatal period, early adolescence, and later adolescence, when reproductive implications become important. Neonatal screening programs should develop systems that allow referring physicians to easily access the results of neonatal screening electronically. Harmonization of practices should allow a better analysis of the consequences of this counselling on family projects.
Collapse
Affiliation(s)
- Narcisse Elenga
- Pediatric Medicine and Surgery, Hôpital Andrée Rosemon, Rue des flamboyants, BP 6006, 97306 Cayenne Cedex, French Guiana
- Sickle Cell Reference Center, Pediatric Medicine and Surgery, Centre Hospitalier de Cayenne “Andrée Rosemon” Rue de Flamboyants, BP 6006, 97306 Cayenne Cedex, French Guiana
| |
Collapse
|
3
|
Rémus C, Stanislas A, Bouazza N, Gauthereau V, Polak M, Blanche S, Niakaté A, Gluckman E, Tréluyer JM, Munnich A, Girot R, Cavazzana M. An Evaluation of Three Ways of Communicating Carrier Status Results to the Parents of Children in a Neonatal Sickle Cell Screening Programme. Front Pediatr 2020; 8:300. [PMID: 32637386 PMCID: PMC7318296 DOI: 10.3389/fped.2020.00300] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/09/2019] [Accepted: 05/11/2020] [Indexed: 11/30/2022] Open
Abstract
Aim: Sickle cell disease (SCD) is the most frequent monogenic disease worldwide; ~5-7% of the world population carry a hemoglobin disorder trait. In the US, one in every 1,941 newborns has SCD, whereas one in every 3,000 newborns in France is affected - resulting in 385 new cases and 5,883 newly identified carriers per year. The objective of the present study was to evaluate three different ways of providing information to parents at risk of having a child with SCD, with a view to increasing the parental screening rate and decreasing the number of new cases per year in France. Method: In a randomized study, we contacted 300 couples of parents after their child had been identified as a SCD carrier in the French national newborn screening programme: 100 couples received an information letter (the standard procedure in France: arm A), 100 couples received a letter and then a follow-up phone call (arm B), and 100 received a letter and then three follow-up text messages at 5-day intervals (arm C). The primary endpoint was the number of parents in each arm screened in the 120 days after the letter had been sent. In a modified intention-to-treat analysis, the screening rate was 17% in arm A, 35% in arm B, and 30% in arm C. Results: Telephone and text message follow-ups were associated with higher screening rates, compared with no follow-up. After being informed of their child's carrier status, some parents had consulted a healthcare professional but had not been referred for screening (16% in arm A, 19% in arm B, and 13% in arm C). Conclusion: A letter followed by a phone call or three text messages is more effective than a letter alone for informing parents at risk of having a child with SCD. The effective implementation of this follow-up programme probably requires better training of all the healthcare professionals involved.
Collapse
Affiliation(s)
- Christelle Rémus
- Département de Génétique, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France.,Centre d'Investigation Clinique de Biothérapie, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France.,Département de Biothérapie, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, INSERM, Paris, France
| | - Aurélie Stanislas
- Centre d'Investigation Clinique de Biothérapie, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France.,Département de Biothérapie, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, INSERM, Paris, France
| | - Naïm Bouazza
- Unité de Recherche Clinique Necker-Cochin, Assistance Publique-Hôpitaux de Paris - EA 7323, Université Paris Descartes Sorbonne Paris Cité, Paris, France
| | - Valérie Gauthereau
- Fédération Parisienne pour le Dépistage, la Prévention du Handicap chez l'Enfant, Paris, France
| | - Michel Polak
- Fédération Parisienne pour le Dépistage, la Prévention du Handicap chez l'Enfant, Paris, France
| | - Stéphane Blanche
- Unité d'Immuno-Hématologie Pédiatrique, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Assa Niakaté
- Centre d'Information et de Dépistage de la Drépanocytose, Paris, France
| | - Eliane Gluckman
- Centre Scientifique de Monaco, Eurocord, Hopital Saint Louis, Université Paris Diderot, Paris, France
| | - Jean-Marc Tréluyer
- Unité de Recherche Clinique Necker-Cochin, Assistance Publique-Hôpitaux de Paris - EA 7323, Université Paris Descartes Sorbonne Paris Cité, Paris, France
| | - Arnold Munnich
- Département de Génétique, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Robert Girot
- Département de Génétique, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France.,Centre d'Investigation Clinique de Biothérapie, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France.,Département de Biothérapie, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, INSERM, Paris, France
| | - Marina Cavazzana
- Centre d'Investigation Clinique de Biothérapie, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France.,Département de Biothérapie, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, INSERM, Paris, France
| |
Collapse
|
4
|
Remion J, Pluchart C. Targeted screening failures in neonates with sickle cell disease in metropolitan France from 2005 to 2017: Number of cases, failure circumstances and health at diagnosis. Arch Pediatr 2019; 26:451-452. [PMID: 31685410 DOI: 10.1016/j.arcped.2019.10.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2019] [Revised: 08/11/2019] [Accepted: 10/06/2019] [Indexed: 11/28/2022]
Affiliation(s)
- J Remion
- EA3801-HERVI, Department of Paediatric Oncology/Hematology, Université, CHU de Reims, CHU de Reims, 47, rue Cognacq Jay, 51092 Reims, France
| | - C Pluchart
- EA3801-HERVI, Department of Paediatric Oncology/Hematology, Université, CHU de Reims, CHU de Reims, 47, rue Cognacq Jay, 51092 Reims, France.
| |
Collapse
|